Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inna Perevozskaya

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Biometrics|July 1, 2011
Discussion: “Bayesian enrichment strategies for randomized discontinuation trials”Inna Perevozskaya
Statistics in Medicine|February 5, 2008
Adaptive dose finding based on t-statistic for dose-response trialsAnastasia Ivanova, James A Bolognese, Inna Perevozskaya
Biometrics|November 7, 2003
Bayesian optimal designs for Phase I clinical trialsLinda M Haines, Inna Perevozskaya, William F Rosenberger
Therapeutic Innovation & Regulatory Science|September 22, 2018
Improving Oncology Clinical Programs by Use of Innovative Designs and Comparing Them via SimulationsOlga Marchenko, Joel Miller, Tom Parke, et al.
Journal of Lipid Research|August 2, 2008
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrateMichel Farnier, Inna Perevozskaya, William V Taggart, et al.
Therapeutic Innovation & Regulatory Science|May 8, 2015
Advances in Statistical Approaches Oncology Drug DevelopmentAnastasia Ivanova, Gary L Rosner, Olga Marchenko, et al.
Journal of Biopharmaceutical Statistics|March 11, 2017
Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?Tom Parke, Olga Marchenko, Vladimir Anisimov, et al.
Statistics in Medicine|February 14, 2025
Using Win Odds to Improve Commit-to-Phase-3 Decision-Making in OncologyBenjamin F Hartley, Thomas Drury, Brian Di Pace, et al.
European Heart Journal|March 23, 2005
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemiaMichel Farnier, Mason W Freeman, Geraldine Macdonell, et al.
Metabolism: Clinical and Experimental|May 27, 2008
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemiaDiane L Tribble, Michel Farnier, Geraldine Macdonell, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Biometrics|July 1, 2011
Discussion: “Bayesian enrichment strategies for randomized discontinuation trials”Inna Perevozskaya
Statistics in Medicine|February 5, 2008
Adaptive dose finding based on t-statistic for dose-response trialsAnastasia Ivanova, James A Bolognese, Inna Perevozskaya
Biometrics|November 7, 2003
Bayesian optimal designs for Phase I clinical trialsLinda M Haines, Inna Perevozskaya, William F Rosenberger
Therapeutic Innovation & Regulatory Science|September 22, 2018
Improving Oncology Clinical Programs by Use of Innovative Designs and Comparing Them via SimulationsOlga Marchenko, Joel Miller, Tom Parke, et al.
Journal of Lipid Research|August 2, 2008
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrateMichel Farnier, Inna Perevozskaya, William V Taggart, et al.
Therapeutic Innovation & Regulatory Science|May 8, 2015
Advances in Statistical Approaches Oncology Drug DevelopmentAnastasia Ivanova, Gary L Rosner, Olga Marchenko, et al.
Journal of Biopharmaceutical Statistics|March 11, 2017
Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?Tom Parke, Olga Marchenko, Vladimir Anisimov, et al.
Statistics in Medicine|February 14, 2025
Using Win Odds to Improve Commit-to-Phase-3 Decision-Making in OncologyBenjamin F Hartley, Thomas Drury, Brian Di Pace, et al.
European Heart Journal|March 23, 2005
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemiaMichel Farnier, Mason W Freeman, Geraldine Macdonell, et al.
Metabolism: Clinical and Experimental|May 27, 2008
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemiaDiane L Tribble, Michel Farnier, Geraldine Macdonell, et al.
Pageof 2